Aristidis Polyzos

2.9k total citations · 1 hit paper
67 papers, 2.4k citations indexed

About

Aristidis Polyzos is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aristidis Polyzos has authored 67 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 16 papers in Surgery and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aristidis Polyzos's work include Cancer Treatment and Pharmacology (19 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Treatments and Mutations (10 papers). Aristidis Polyzos is often cited by papers focused on Cancer Treatment and Pharmacology (19 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Treatments and Mutations (10 papers). Aristidis Polyzos collaborates with scholars based in Greece, United States and Sweden. Aristidis Polyzos's co-authors include Lisa M. Daniels, Janet E. Price, Helen Gogas, Dimosthenis Tsoutsos, George Fountzilas, P. Panagiotou, John M. Kirkwood, Dimitrios Bafaloukos, Dimitrios Pectasides and J. Ioannovich and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Aristidis Polyzos

64 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

1990 534 citations Aristidis Polyzos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aristidis Polyzos Greece	24	1.3k	718	507	481	366	67	2.4k
Pierosandro Tagliaferri Italy	34	1.7k 1.3×	1.1k 1.6×	645 1.3×	449 0.9×	615 1.7×	97	3.2k
S. M. Lippman United States	20	892 0.7×	1.8k 2.5×	303 0.6×	511 1.1×	487 1.3×	48	3.2k
José A. López-Martín Spain	28	1.3k 1.0×	824 1.1×	243 0.5×	601 1.2×	352 1.0×	123	2.4k
Johanna Louhimo Finland	29	770 0.6×	639 0.9×	179 0.4×	348 0.7×	353 1.0×	57	1.9k
G. Deplanque France	23	1.3k 1.0×	633 0.9×	199 0.4×	812 1.7×	542 1.5×	77	2.3k
Jermaine Coward Australia	23	1.2k 0.9×	704 1.0×	404 0.8×	380 0.8×	354 1.0×	87	2.3k
Taher Al‐Tweigeri Saudi Arabia	24	1.7k 1.3×	619 0.9×	729 1.4×	354 0.7×	553 1.5×	61	2.5k
Hidehiro Tajima Japan	29	1.3k 1.0×	725 1.0×	430 0.8×	758 1.6×	380 1.0×	178	2.7k
Ioannis A. Voutsadakis Canada	27	1.2k 1.0×	914 1.3×	187 0.4×	474 1.0×	639 1.7×	161	2.3k
Xiaomei Zhang China	16	768 0.6×	706 1.0×	631 1.2×	268 0.6×	349 1.0×	36	1.9k

Countries citing papers authored by Aristidis Polyzos

Since Specialization

Citations

This map shows the geographic impact of Aristidis Polyzos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aristidis Polyzos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aristidis Polyzos more than expected).

Fields of papers citing papers by Aristidis Polyzos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aristidis Polyzos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aristidis Polyzos. The network helps show where Aristidis Polyzos may publish in the future.

Co-authorship network of co-authors of Aristidis Polyzos

This figure shows the co-authorship network connecting the top 25 collaborators of Aristidis Polyzos. A scholar is included among the top collaborators of Aristidis Polyzos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aristidis Polyzos. Aristidis Polyzos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pančoška, Petr, John M. Kirkwood, Maria Spyropoulou‐Vlachou, et al.. (2014). A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE. 9(1). e86375–e86375. 2 indexed citations

Gogas, Helen, et al.. (2014). Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Letters. 347(2). 175–182. 55 indexed citations

Gogas, Helen, Aristidis Polyzos, & John M. Kirkwood. (2013). Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treatment Reviews. 39(8). 879–885. 38 indexed citations

Mavroudis, Dimitriοs, Pavlos Papakotoulas, Alexandros Ardavanis, et al.. (2009). Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Annals of Oncology. 21(1). 48–54. 31 indexed citations

Terzidis, Agis, Theodoros Ν. Sergentanis, Anna Efremidis, et al.. (2008). Elevated Serum Leptin Levels: A Risk Factor for Non-Small-Cell Lung Cancer?. Oncology. 76(1). 19–25. 28 indexed citations

Kosmas, Christos, Νicolas Tsavaris, Nikolaos Malamos, et al.. (2007). Docetaxel–ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Investigational New Drugs. 25(5). 463–470.

Gogas, Helen, J. Ioannovich, Urania Dafni, et al.. (2006). Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. New England Journal of Medicine. 354(7). 709–718. 428 indexed citations

Boukovinas, Ioannis, N. Androulakis, L. Vamvakas, et al.. (2006). Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Annals of Oncology. 17(11). 1687–1692. 11 indexed citations

Gogas, Helen, Aristidis Polyzos, Konstantina Frangia, et al.. (2006). Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 17(12). 1835–1841. 19 indexed citations

10.

Potamianou, Anna, Nikolaos Androulakis, Pavlos Papakotoulas, et al.. (2005). Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer. Oncology. 69(4). 348–353. 9 indexed citations

11.

Kosmas, Christos, Νicolas Tsavaris, Thomas Makatsoris, et al.. (2005). A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer. Oncology. 69(4). 333–341. 2 indexed citations

12.

Georgoulias, Vassilis, Athina Agelidou, K. Syrigos, et al.. (2005). Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. British Journal of Cancer. 93(7). 763–769. 38 indexed citations

13.

Souglakos, John, Konstantinos Syrigos, Anna Potamianou, et al.. (2004). Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Annals of Oncology. 15(8). 1204–1209. 41 indexed citations

14.

Georgoulias, Vassilis, Ch. Kouroussis, Athina Agelidou, et al.. (2004). Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. British Journal of Cancer. 91(3). 482–488. 51 indexed citations

15.

Gogas, Helen, Dimitrios Bafaloukos, Gerasimos Aravantinos, et al.. (2004). Vinorelbine in Combination with Interleukin-2 as Second-Line Treatment in Patients with Metastatic Melanoma. A Phase II Study of the Hellenic Cooperative Oncology Group. Cancer Investigation. 22(6). 832–839. 8 indexed citations

16.

Kosmas, Christos, et al.. (2003). Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. British Journal of Cancer. 88(8). 1168–1174. 7 indexed citations

17.

Polyzos, Aristidis, et al.. (2003). Irinotecan as Salvage Chemotherapy for Advanced Small Bowel Adenocarcinoma: A Series of Three Patients. Journal of Chemotherapy. 15(5). 503–506. 27 indexed citations

18.

Polyzos, Aristidis, N. Tsavaris, Christos Kosmas, et al.. (1999). Second-Line Chemotherapy with Cisplatin-Ifosfamide in Patients with Ovarian Cancer Previously Treated with Carboplatin-Cyclophosphamide. Journal of Chemotherapy. 11(2). 144–149. 7 indexed citations

19.

Polyzos, Aristidis, Νicolas Tsavaris, Christos Kosmas, et al.. (1999). A Comparative Study of Intraperitoneal Carboplatin versus Intravenous Carboplatin with Intravenous Cyclophosphamide in Both Arms as Initial Chemotherapy for Stage III Ovarian Cancer. Oncology. 56(4). 291–296. 80 indexed citations

20.

Buzdar, Aman U., et al.. (1987). Problems in the Identification of a Cancer Family. American Journal of Clinical Oncology. 10(6). 531–534. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact